Advancements and Insights in Non–Muscle-Invasive Bladder Cancer: Emerging PD-1/PD-L1 Inhibitors : Episode 8
Opinion
Video
Examining the Effects of PD-1/PD-L1 Inhibitor Differences on Patient Outcomes: Adherence, BCG Maintenance, and Resource Management
Key Takeaways
- Disparities in clinical guidelines and access to therapies can lead to varied treatment outcomes in uro-oncology.
- Patient adherence is influenced by treatment complexity, financial constraints, and healthcare professional support.
Panelists discuss how the differences in routes of administration, durations of therapy, and control arms among PD1/PD-L1 inhibitors in trials may impact patient care, resource utilization, and treatment adherence, highlighting key insights from recent Uro Oncology presentations.
Video Player is loading.
Video content above is prompted by the following:
- Explain how these differences may impact patient care, resource use, and adherence. [Uro Oncology presentation by Psutka]Bedke 2023
Related Videos
Optimizing Multidisciplinary Care for BCG-Naive, High-Risk NMIBC
Exploring Emerging Data in NMIBC
Phase 3 Trials of PD-1/PD-L1 Inhibitors in NMIBC
Navigating PD-1/PD-L1 Agents: Influential Factors in Choosing the Right Therapy
Collaborative Strategies: Urologists and Oncologists Enhancing Outcomes for High-Risk NMIBC
Innovations in NMIBC Treatment: The Synergy of BCG and PD-1/PD-L1 Inhibitors
Exploring PD-1/PD-L1 Pathways and Innovative Treatments for NMIBC
NMIBC Treatment Insights: Standard of Care, BCG Immune Response, and Patient Outcomes
Exploring NMIBC: Overview, Symptoms, Risk Factors and Staging
Related Content
